2016
Natural history of postural instability in breast cancer patients treated with taxane-based chemotherapy: A pilot study
Monfort S, Pan X, Patrick R, Singaravelu J, Loprinzi C, Lustberg M, Chaudhari A. Natural history of postural instability in breast cancer patients treated with taxane-based chemotherapy: A pilot study. Gait & Posture 2016, 48: 237-242. PMID: 27341530, PMCID: PMC4969166, DOI: 10.1016/j.gaitpost.2016.06.011.Peer-Reviewed Original ResearchConceptsBreast cancer patientsTaxane-based chemotherapyCancer patientsPostural instabilityChemotherapy cyclesBalance impairmentNatural historyCOP excursionPilot studyCoP ellipse areaSubsequent chemotherapy cyclesFirst chemotherapy cycleEyes-closed conditionTaxane exposureTaxane infusionEllipse areaOncology clinicConfidence ellipse areaPatient populationChemotherapy treatmentAdverse symptomsBreast cancerBaseline valuesEffective treatmentSide effects
2014
A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer
Zhao M, Pan X, Layman R, Lustberg M, Mrozek E, Macrae E, Wesolowski R, Carothers S, Puhalla S, Shapiro C, Ramaswamy B. A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Investigational New Drugs 2014, 32: 1285-1294. PMID: 24894652, PMCID: PMC4303337, DOI: 10.1007/s10637-014-0122-5.Peer-Reviewed Original ResearchConceptsProgression-free survivalLeft ventricular ejection fractionClinical benefit rateHER2-positive MBCObjective response rateComplete responsePartial responseBreast cancerStable diseaseFree survivalGrade 3HER2-positive metastatic breast cancerResponse rateAdditional overall survival benefitsMedian progression-free survivalMetastatic breast cancer patientsPositive metastatic breast cancerVascular epithelial growth factorCommon grade 3Cycles of bevacizumabGrade 2 hypertensionMethods Eligible patientsPrior chemotherapy regimensCombination of bevacizumabHand-foot syndrome
2013
Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review
Poi M, Berger M, Lustberg M, Layman R, Shapiro C, Ramaswamy B, Mrozek E, Olson E, Wesolowski R. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Supportive Care In Cancer 2013, 21: 2679-2686. PMID: 23686402, PMCID: PMC3769512, DOI: 10.1007/s00520-013-1842-3.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSkin toxicityCancer patientsCase seriesGranulocyte colony-stimulating factor supportToxicity eventsColony-stimulating factor supportDose-dense doxorubicinOperable stage IResultsThirty-four patientsSevere skin toxicityEvidence-based preventionElectronic medical recordsInstitutional review boardDermatologic toxicitiesDocetaxel 75Docetaxel monotherapyWeekly paclitaxelCyclophosphamide regimenClinical courseFactor supportMedical recordsTreatment strategiesGrade 3Inclusion criteria